HBV-IN-25

Category	Hepatitis B Virus (HBV)
CAS	2161364-69-6
Description	HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA(cid:0)452 μg/mL) and good PK property with no cellular toxicity.

Quotation Now

Molecular Weight	343.76
Molecular Formula	C18H14ClNO4
Purity	≥98% (HPLC)
Solubility	10 mM in DMSO
Appearance	Solid powder
Storage	Store at -20°C
In Vitro	HBV-IN-25 (8-50 μM, 5 days) has anti-HBeAg potency with an IC50 value of 0.58 μM. HBV-IN-25 (8-50 μM, 5 days) has the anti-HBV activity in PHH is maintained or slightly decreased with IC50 value of 1.15 μM.
In Vivo	HBV-IN-25 (oral, 5, 20, 100, 300 mg/kg, single) has good PK property, and also shows excellent efficacy in significantly reducing HBV antigens, DNA, and intrahepatic cccDNA levels. Pharmacokinetic Parameters of HBV-IN-25 inHBVcircle mouse model (oral, 5, 20, 100, 300 mg/kg, single).
Target	IC50: 0.58 μM (anti-HBeAg); 1.15 μM (anti-HBV)